Oncology

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

New DDW Highlights episode now available

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The most impactful drug discovery news this week is all linked with scientific research… Read More

#News

Multiple myeloma
#Bispecific Antibodies #Cancer research #CHMP #EMA #Janssen #Myeloma #Oncology

CHMP recommendation for bispecific antibody talquetamab

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended conditional marketing authorisation for Janssen’s Talvey (talquetamab). The drug has received a positive opinion for use as a monotherapy for the treatment of adult patients with… Read More

#News #Regulatory

#Biomedical research #Clinical trials #Laboratory data #Long Covid #Neuroscience #Oncology #Trial data

This week in drug discovery (17-21 July)  

News round-up for 17-21 July by DDW Digital Content Editor Diana Spencer. The most impactful drug discovery news this week is all linked with scientific research data. Analysts Phesi revealed that a third of clinical development programmes are cancelled during Phase II, and there were significant… Read More

#News

#BioIVT #Biospecimen collection #Mergers and acquisitions #Neurology #Oncology #PrecisionMed

BioIVT acquires biospecimens provider PrecisionMed

BioIVT has acquired PrecisionMed, a supplier of human biological material for genetics, drug discovery, and biomarker research and in vitro diagnostics. Based in Carlsbad, CA, US, PrecisionMed has been collecting biospecimens for neurology and oncology research for more than 27 years, and reportedly has the largest… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Cancer research #Genetics / genomics #Oncology

Open science, genomics, and the quiet revolution in our approach to pharma

Listen to this article on the DDW Podcast: Evan Floden, CEO of Seqera Labs examines how data sharing platforms are impacting cancer and genomics research. The tide has been turning in the worlds of diagnostics and drug development. Bioinformatics and genetic sequencing are… Read More

#Cancer Research #Exclusive Content

CRISPR gene editing
#Cancer research #CAR-T #CRISPR #CRISPR-Cas9 #Gene editing #Oncology

CRISPR breakthroughs: New solutions for common diseases

Listen to this article on the DDW Podcast: Rolf Turk, Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Since its discovery in 2012, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionised… Read More

#Cancer Research #Exclusive Content

Monoclonal antibodies
#Astellas Pharma #Cancer research #EMA #Gastrointestinal #Monoclonal antibodies #Oncology

EMA reviews monoclonal antibody for gastric cancer

The European Medicines Agency (EMA) has accepted for regulatory review Astellas Pharma’s marketing authorisation application (MAA) for zolbetuximab, an investigational Claudin 18.2 (CLDN18.2)-targeted monoclonal antibody. The application is for authorisation as a first-line treatment of patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal… Read More

#News #Regulatory

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

DDW Highlights podcast: New episode

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Despite the bad news for the UK life sciences industry this week that international investment dropped… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trial design #Clinical trials #Oncology #Phase II trial

A third of clinical trials cancelled during Phase II

Analysis of 13,490 clinical trials finds almost a third have been cancelled during Phase II amidst an overall decline in clinical development productivity. Data analytics company Phesi has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date. Read More

#News #Trending News

#Artificial intelligence (AI) #Cell and gene therapy #Funding #Investment #Oncology #Private investment #Synthetic biology #UK

This week in drug discovery (3-7 July)  

News round-up for 10-14 July by DDW Digital Content Editor Diana Spencer. Despite the bad news for the UK life sciences industry this week that international investment dropped nearly 50% in 2022, both private and public funding activity has continued apace in the wider drug discovery… Read More

#News

#Artificial intelligence (AI) #Cancer research #Collaboration #Oncology #Precision medicine #The Institute of Cancer Research #Vivan Therapeutics

AI discovery collaboration targets precision cancer drugs

Researchers will combine expertise in drug discovery, artificial intelligence (AI), and experimental cancer models and platforms in a new programme to design the precision cancer drugs of the future. Under an academic and commercial collaboration between The Institute of Cancer Research, London, the Bellvitge Biomedical Research… Read More

#Cancer Research #News

Lung cancer
#Cancer research #Immunotherapy #Lung cancer #Oncology #Roche #University College London

Immunotherapy improves lung cancer long-term survival

A global study, led by University College London (UCL) and University College London Hospitals (UCLH) and sponsored by Roche, has shown that the cancer immunotherapy atezolizumab significantly improved the overall survival of advanced stage non-small cell lung cancer (NSCLC) patients, when compared to single-agent chemotherapy. For… Read More

#Cancer Research #News

#Animal models #Cancer immunotherapy #Cell therapy #Covid-19 #Humanised Immune System (HIS) #Immunotherapy #Monoclonal antibodies #Mouse models #Oncology #Regulatory

Podcast: Immunotherapy, avelumab and the immunocompromised

This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised”, which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “Mice with humanised immune systems advance cell-based immunotherapy”, “… Read More

#News

Oncology Research Concept
#Cancer research #Drug discovery #Haematology #Oncology

Q&A with Mark Garner: The golden age of cancer research  

Mark Garner, PhD., Global Cancer Segment Market Manager at Agilent Technologies, recently sat down with DDW Editor Reece Armstrong to tell us about the developments in the ‘golden age’ of cancer research.  RA: Please can you tell us a bit more about your role at Agilent?… Read More

#Exclusive Content

Stock market
#AstraZeneca #Business #Cancer research #Lung cancer #Oncology #Trial data

AstraZeneca stock value falls by 8%

Shares in AstraZeneca fell by 6% on July 3 when the company published the first results from its Phase III trial for datopotamab deruxtecan (Dato-DXd) and continued to fall throughout the day, though there was some recovery on July 4. It was reported that the therapy… Read More

#Business & Investment #News #Trending News

Natural killer cells
#Cancer research #Cell therapy #EU patent #iPSC #Oncology #ONK Therapeutics

ONK secures European patent for CISH knockout in NK cells

The European Patent Office (EPO) has granted a licensed patent to ONK Therapeutics covering CISH knockout (KO) in natural killer (NK) cells, irrespective of the source of the NK cells. The patent includes human cord blood-derived, peripheral blood-derived, and NK cells derived from induced pluripotent stem… Read More

#Cancer Research #News